Mindbloom vs. Kalm: Which At-Home Ketamine Program Fits You?

Mindbloom vs. Kalm at a Glance

Both providers treat you at home, so the core difference is the type of treatment: Kalm delivers a daily low-dose troche on an open-ended subscription, while Mindbloom delivers periodic therapeutic-dose sessions inside a defined program. Kalm's advantages are a lower monthly price and a non-dissociative format; Mindbloom's are published outcomes, two medication routes, and a full support program.

Table note: Kalm details reflect Kalm's website as of October 2026.⁵ Mindbloom details reflect Mindbloom's new-client program information.

If you want to see how Mindbloom vs Kalm fits into the wider market, read our guide to at-home ketamine providers compared.

Mindbloom vs. Kalm: Each Provider on Its Own Terms

Mindbloom and Kalm are both US telehealth providers that prescribe ketamine for use at home after an online evaluation, and neither requires clinic visits. Beyond that, they take fundamentally different approaches: Mindbloom prescribes therapeutic doses for periodic guided sessions, and Kalm prescribes low doses for daily use.

1. Mindbloom

Mindbloom provides guided at-home ketamine therapy and has facilitated more than 850,000 supervised sessions. You select a 6, 12, or 18-session program, and a licensed provider then conducts a medical evaluation to confirm your eligibility and personalize your care. Mindbloom offers two medication routes, sublingual tablets and subcutaneous Injectables, and serves clients in 38 states.

Mindbloom has published three peer-reviewed studies on its own clients, beginning with a 2022 study of 1,247 tablet clients (Hull 2022).⁴

Main features:

• Provider consults: two to four per program, based on program length.
• Guided sessions: therapeutic-dose sessions at home, led by the Mindbloom App.
• Two routes: sublingual tablets or subcutaneous Injectables.
• Integration support: guide coaching plus unlimited Group Integration Circles.

Ideal for:

• People looking for peer-reviewed outcomes on par with in-clinic IV ketamine, without going to a clinic.
• People who have tried antidepressants or talk therapy without enough relief.
• People who want a choice of medication route: sublingual tablets or subcutaneous injections.

Pricing:

• 6 sessions: $215 per session.
• 12 sessions: $185 per session.
• 18 sessions: $165 per session.
• Payment: monthly installments, HSA/FSA eligible.

2. Kalm

Kalm, also called Kalm Health (kalmhealth.org), is a platform that provides services to affiliated, independently owned psychiatric practices. Kalm prescribes ketamine in small daily doses, which it calls low-dose, as buccal troches or orally dissolving tablets (ODTs), and describes its troches as non-psychedelic and non-dissociative.⁵

The subscription costs $124 per month with no commitment and includes 30 doses a month, an initial consultation with a doctor, unlimited check-ins, and shipping. Kalm describes itself as the only provider licensed and available in all 50 states (its licensure page currently lists 44 states plus Washington, DC, so check your state during screening).⁵

Main features:

• Doctor consultation: an initial consultation with a licensed provider, plus unlimited check-ins.
• Daily dosing: a low-dose troche or ODT taken at home each day.
• Daily check-ins: required reports on side effects and mood changes.
• Messaging: support 7 days a week through the patient portal.

Ideal for:

• People who want the lowest monthly price.
• People who want to avoid a dissociative or psychedelic-like experience.

Pricing:

• Monthly price: $124, no commitment.
• Price guarantee: a 20% price-beat guarantee.
• Payment: HSA/FSA eligible.

How the Treatment Models Differ: Guided Therapeutic-Dose Sessions vs. Kalm's Daily Troches

At-home ketamine therapy is not one treatment. Kalm uses a daily low dose designed to avoid dissociation, while Mindbloom uses periodic guided sessions at a therapeutic, sub-anesthetic dose.

How Kalm's Model Works

Kalm's model is a daily medication routine rather than a session: you take a low-dose buccal troche (or an orally dissolving tablet) at home each day on a month-to-month subscription. Kalm calls this psycholytic dosing (several patient reviews on its site call it microdosing) and describes the effect as relaxed and less anxious while fully aware, without dissociation or hallucinations, fading within about 2.5 hours.⁵

Getting started involves an online pre-qualification quiz, an intake form, and an initial consultation with a licensed provider, who decides whether to prescribe. If you are approved, at least a month's supply ships to your door, usually within 7 to 10 business days. After that, Kalm requires daily check-ins to report side effects or mood changes, and you can message your doctor through the patient portal.⁵

Because there is no session, Kalm's plan does not include a guide, preparation or integration coaching, or group support, and Kalm does not list any requirement for someone to be present when you take a dose. Kalm does advise against driving or operating machinery after dosing.⁵

Kalm has not published outcomes data on this protocol, and daily low-dose oral ketamine has been tested in only one small published trial, which involved hospice patients rather than the general public (Irwin 2013).³ For the full research review, see Mindbloom's guide to daily low-dose ketamine protocols.

How Mindbloom's Model Works

A Mindbloom session is a therapeutic-dose ketamine experience you take at home, following the Mindbloom App, with a peer treatment monitor you choose present. Sessions typically last 60 to 90 minutes, and how often you have them is personalized rather than fixed.

Two people support you around those sessions. A licensed clinician evaluates you before treatment, sets your dose, and checks in periodically to review your progress and adjust it. A guide meets with you before your first session to help you prepare, then periodically throughout your program to help you integrate your experiences.

During a session, you take a sublingual tablet or a subcutaneous injection and follow the app. A therapeutic dose produces a dissociative, psychedelic-like state that many people find therapeutically meaningful, which is why a peer treatment monitor is required at every session to provide practical support. Afterward, plan to rest, and avoid driving or operating machinery until after a full night of sleep.

Improvement often starts early and builds across the course. In Mindbloom's 2026 study of 3,041 clients using Injectables (Parks 2026), 70.2% reached clinically meaningful improvement in depression by their second session, about two weeks in, and 81.8% had by the end of the six-session course.² On tablets, 89% of 11,441 clients reported improvement by their fourth session (Mathai 2024).¹

Sublingual Tablets, Subcutaneous Injectables, and Buccal Troches

Kalm's buccal troches and Mindbloom's sublingual tablets work the same way: both are held in the mouth and absorbed through its lining. The difference between the two providers' oral options is the dose and how often you take it, not the form: Kalm prescribes a low dose for daily use, and Mindbloom prescribes a therapeutic dose for periodic sessions.

Mindbloom also offers a second route. Mindbloom Injectables are subcutaneous injections given with a small insulin needle into the skin of the abdomen, and Mindbloom is the only at-home ketamine provider we identified in October 2026 that offers them, which also makes it the only one offering a choice between sublingual and subcutaneous treatment.

Which route suits you depends on comfort with needles, personal preference, tolerability, and medical fit, and your clinician helps you decide.

Is Daily Low-Dose Ketamine Safe for Long-Term Use?

The long-term safety of daily low-dose ketamine is unknown. As of this writing, the longest published trial of daily oral ketamine for depression lasted 28 days and enrolled 14 hospice patients (Irwin 2013),³ and no published study has measured tolerance, dependence, or withdrawal over the months or years a month-to-month subscription like Kalm's can run.

Kalm describes its troches as "safe for most patients" and its doses as "much lower than those typically associated with addiction,"⁵ but that comparison is to recreational misuse of 1 to 4 grams a day, not to a study of Kalm's own patients.

What the Clinical Evidence Shows for Mindbloom and Kalm

The evidence base is one of the clearest differences between the two approaches. Mindbloom has published peer-reviewed outcomes on more than 14,000 of its own clients across tablets and Injectables, while daily low-dose ketamine, the approach Kalm uses, has not yet been studied in a published trial of general outpatients. Browse the studies on Mindbloom's research studies page.

Mindbloom's Published Outcomes From Three Peer-Reviewed Studies

• Depression: 56.4% of tablet clients and 56.6% of Injectables clients met response criteria (Mathai 2024; Parks 2026),¹⁻² on par with real-world IV ketamine (53.6%; McInnes 2022).⁶
• Anxiety: 56.1% of tablet clients and 60.6% of Injectables clients met response criteria (Mathai 2024; Parks 2026).¹⁻²
• PTSD: Mindbloom is the only at-home ketamine provider with peer-reviewed PTSD outcomes: 76.7% of Injectables clients met response criteria (Parks 2026).²
• Durability: 84% of tablet clients who improved held that improvement through a second course (Mathai 2024).¹ Read Mindbloom's summary of this 11,441-patient real-world study.

Mindbloom's first study found a 62.8% depression response rate (Hull 2022);⁴ see the summary of Mindbloom's 2022 prospective study. Mindbloom also offers dedicated programs for depression, anxiety, and PTSD. These are real-world results from Mindbloom's own program, not placebo-controlled trials. Individual results may vary.

Kalm's Reported Results and What Has Not Been Published

Kalm has not published outcomes data on its protocol. Its Results page points to broader ketamine research rather than to data on its daily low-dose approach.⁵ The closest published trial of once-daily oral ketamine enrolled 14 hospice patients for 28 days (Irwin 2013),³ and a 2022 pilot of oral esketamine taken three times daily found no responders among 7 patients (Smith-Apeldoorn 2022).⁷

What the Safety Data Shows

Serious side effects are uncommon in supervised ketamine treatment: a 2024 review of 93 trials found them in about 0.1% of participants (Hovda 2024).⁸ In Mindbloom's at-home studies, serious adverse events occurred in 0.05% of tablet clients and 0.08% of Injectables clients (Mathai 2024; Parks 2026).¹⁻² When side effects occur, they can include nausea, dizziness, or a temporary rise in blood pressure, which is why blood pressure screening is part of intake. Kalm has not published safety data on its protocol.

Mindbloom vs. Kalm Pricing: What Each Program Costs and Includes

Kalm costs $124 per month, while Mindbloom's new-client programs cost $165 to $215 per session, paid in monthly installments. The numbers look far apart because they measure different things: a month of daily doses versus a guided session with a care team around it.

Kalm Monthly Subscription Pricing

Kalm's subscription costs $124 per month once you are approved, with no commitment, and includes 30 buccal troche doses, a doctor consultation, unlimited check-ins, and shipping. Kalm also offers a 20% price-beat guarantee.⁵

Mindbloom Program Pricing for 6, 12, or 18 Sessions

How much Mindbloom costs depends on program length; longer programs lower the per-session price. You choose a program at purchase based on your goals and budget, and a licensed provider then evaluates your eligibility.

Every program includes clinician consults, guide coaching, and unlimited Group Integration Circles. See current details on Mindbloom program pricing options.

Cost Per Session vs. Cost Per Month: What You Are Paying For

Per month, Kalm costs less. Over time, the comparison depends on how long you stay on it: each Mindbloom program has a defined total, from $1,290 for 6 sessions to $2,970 for 18, while Kalm's subscription has no set end date, so six months costs $744 and a year costs $1,488.

HSA/FSA Eligibility and Payment Options

Both providers accept HSA or FSA funds. Mindbloom does not bill insurance directly but provides a Superbill, a detailed receipt you can submit for potential partial reimbursement, which varies by plan. Confirm the details with your plan administrator before you pay.

What Are the Pros and Cons of Mindbloom vs. Kalm?

Kalm's main pros are price and convenience: $124 a month and a non-dissociative daily dose with no session to plan; its main con is evidence, since Kalm has not yet published outcomes research and its daily protocol has not been studied beyond 28 days. Mindbloom's main pros are peer-reviewed outcomes on both routes (89% of tablet clients reported depression improvement; 81.8% on Injectables saw clinically meaningful improvement), two medication routes, and a full care team; its main cons are a higher upfront cost and set-aside time for each session.¹⁻²

Choose Mindbloom if you want a treatment with published evidence behind it. Choose Kalm if a low monthly price and a non-dissociative daily routine are your priorities, with the understanding that its daily low-dose protocol has not yet been studied in published trials.

Kalm Pros and Cons

Pros:

• Low monthly price: $124 per month, with a 20% price-beat guarantee.
• Nothing to schedule: a daily dose with no session to plan.
• Designed to be non-dissociative, for people who want to avoid an altered state.
• Wide availability: 50 states per Kalm's main page (44 states plus Washington, DC, per Kalm's licensure page).
• HSA/FSA eligible.

Cons:

• No published outcomes on its protocol.
• Untested approach: daily low-dose oral ketamine has been tested in one published trial, of 14 hospice patients over 28 days (Irwin 2013).
• Unknown long-term safety: no published study has measured dependence, tolerance, or withdrawal from months of daily low-dose ketamine.
• Open-ended cost: no set end point; a year costs $1,488.
• No driving or operating machinery after each dose.
• Oral only, with no guide coaching or integration support.

Best fit if monthly price is your deciding factor, you want to avoid any dissociative experience, or you live in a state Mindbloom does not serve.

Mindbloom Pros and Cons

Pros:

• Published outcomes on both routes, including the only peer-reviewed PTSD outcomes from an at-home ketamine provider (76.7% response, Parks 2026).
• Two routes: sublingual tablets or subcutaneous Injectables, the only at-home subcutaneous option.
• Full care team: 2 to 4 clinician consults, 3 to 5 guide coaching sessions, and unlimited Group Integration Circles per program.
• Guided, therapeutic-dose sessions with a peer treatment monitor present.
• HSA/FSA eligible, with a Superbill for possible partial reimbursement.

Cons:

• Higher upfront cost: $1,290 to $2,970 per program.
• Each session takes set-aside time and a peer treatment monitor.
• Available in 38 states.

Best fit if you want results on par with IV ketamine therapy and/or you are open to a dissociative session experience with clinician and guide support built in.

Important Safety Information

IMPORTANT SAFETY INFORMATION Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

OFF-LABEL USE DISCLOSURE Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.